
Opinion|Videos|January 22, 2025
Safety Profile of Second-Line Agent in Patients With Compensated Cirrhosis
Panelists discuss how the safety profiles of second-line primary biliary cholangitis (PBC) therapies in compensated cirrhosis show varying levels of risk, with recent abstracts from EASL and AASLD 2024.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do the safety profiles of seladelpar, elafibranor, and obeticholic acid impact their use in patients with compensated cirrhosis?
- Include in your discussion the EASL 2024 abstract.
- Include in your discussion the EASL 2024 abstract.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Medicare Is Finally Covering GLP-1s for Weight Loss: What the Bridge Program Means for Your Practice
2
Updated 2025-2026 COVID-19 Vaccine Nearly Halved ED Visits, Hospitalizations in CDC-Funded Study
3
FDA Narrows Compounding Rules for GLP-1s: How Pharmacists Should Respond
4
The Biosimilar Conversation Nobody Is Having at the Pharmacy Counter: Why Adoption Is Still Struggling and What We Can Do About It
5

















































































































